What to expect when you take Calcitonin-salmon and Zantac?

Do you take Calcitonin-salmon and Zantac? Find out below what new side effects and undetected conditions people who are 50-59 years old may have. This prediction is created after we perform predictive analysis on health care big data. It will be updated regularly.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.

Who is eHealthMe: we are a data analysis company who specializes in health care industry. Our original studies have been referenced on 500+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and EANO. On eHealthMe, you can research drugs and monitor them (see testimonials). If you find eHealthMe useful, please help us to spread the words below or leave us a testimonial.



On Jan, 11, 2019

9,093 reports have been studied.


Females aged 50 to 59 :

5,584 related reports were analyzed:

Most common symptoms:

Abdominal pain
  • 20.18% for females aged 50 (±5) who take Calcitonin-salmon
Acute kidney failure
  • 23.68% for females aged 50 (±5) who take Calcitonin-salmon
Adrenal insufficiency
  • 8.77% for females aged 50 (±5) who take Calcitonin-salmon
Anaemia
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
Anhedonia
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Appendicitis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Aptyalism
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Arthritis
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
Aseptic necrosis
  • 8.77% for females aged 50 (±5) who take Calcitonin-salmon
Asthma
  • 21.93% for females aged 50 (±5) who take Calcitonin-salmon
Back pain
  • 9.65% for females aged 50 (±5) who take Calcitonin-salmon
Blood alkaline phosphatase increased
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Blood glucose increased
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
Bone disorder
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
Bone erosion
  • 23.68% for females aged 50 (±5) who take Calcitonin-salmon
Bone fragmentation
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Bone lesion
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
Bone pain
  • 27.19% for females aged 50 (±5) who take Calcitonin-salmon
Broken bone
  • 10.53% for females aged 50 (±5) who take Calcitonin-salmon
Bursitis
  • 19.3% for females aged 50 (±5) who take Calcitonin-salmon
Cardiac failure congestive
  • 11.4% for females aged 50 (±5) who take Calcitonin-salmon
Cellulitis
  • 23.68% for females aged 50 (±5) who take Calcitonin-salmon
Chest pain
  • 7.04% for females aged 50 (±5) who take Zantac
Chronic obstructive pulmonary disease
  • 7.89% for females aged 50 (±5) who take Calcitonin-salmon
Cor pulmonale chronic
  • 10.53% for females aged 50 (±5) who take Calcitonin-salmon
Dental caries
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Depression
  • 8.77% for females aged 50 (±5) who take Calcitonin-salmon
Device failure
  • 20.18% for females aged 50 (±5) who take Calcitonin-salmon
Diabetes
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
Diarrhea
  • 30.7% for females aged 50 (±5) who take Calcitonin-salmon
  • 6.64% for females aged 50 (±5) who take Zantac
Disability
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Diverticulum
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
Dizziness
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
  • 5.69% for females aged 50 (±5) who take Zantac
Drug ineffective
  • 5.96% for females aged 50 (±5) who take Zantac
Dry mouth
  • 11.4% for females aged 50 (±5) who take Calcitonin-salmon
Dyspnea
  • 6.36% for females aged 50 (±5) who take Zantac
Encephalopathy
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Enteritis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Enterococcal infection
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Escherichia infection
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Essential thrombocythaemia
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Exostosis
  • 25.44% for females aged 50 (±5) who take Calcitonin-salmon
Facial neuralgia
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Fall
  • 10.53% for females aged 50 (±5) who take Calcitonin-salmon
  • 5.34% for females aged 50 (±5) who take Zantac
Fatigue
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
  • 7.22% for females aged 50 (±5) who take Zantac
Fever
  • 14.91% for females aged 50 (±5) who take Calcitonin-salmon
  • 5.21% for females aged 50 (±5) who take Zantac
Fibrocystic breast disease
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Foot deformity
  • 14.04% for females aged 50 (±5) who take Calcitonin-salmon
Foot fracture
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
Gait disturbance
  • 11.4% for females aged 50 (±5) who take Calcitonin-salmon
Gastroduodenitis
  • 10.53% for females aged 50 (±5) who take Calcitonin-salmon
Gastroenteritis
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Gastroesophageal reflux disease
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
Generalised oedema
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Gingival infection
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Gingival pain
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Gingivitis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Gums - swollen
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Haemangioma
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Haemorrhage intracranial
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
Headache
  • 12.28% for females aged 50 (±5) who take Calcitonin-salmon
  • 6.44% for females aged 50 (±5) who take Zantac
Hearing loss
  • 7.89% for females aged 50 (±5) who take Calcitonin-salmon
Hepatic steatosis
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Humerus fracture
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Hypercalcaemia
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Hyperglycemia
  • 14.91% for females aged 50 (±5) who take Calcitonin-salmon
Hypoaesthesia
  • 13.16% for females aged 50 (±5) who take Calcitonin-salmon
Hypogammaglobulinaemia
  • 14.91% for females aged 50 (±5) who take Calcitonin-salmon
Hypotension
  • 9.65% for females aged 50 (±5) who take Calcitonin-salmon
Impaired healing
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
Increased tendency to bruise
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Injury
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
Insomnia
  • 10.53% for females aged 50 (±5) who take Calcitonin-salmon
Intervertebral disc disorder
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
Intervertebral disc protrusion
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
Joint dislocation
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Joint pain
  • 7.89% for females aged 50 (±5) who take Calcitonin-salmon
Lumbar spinal stenosis
  • 17.54% for females aged 50 (±5) who take Calcitonin-salmon
Lung disorder
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
Malocclusion
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Mastication disorder
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Metastatic neoplasm
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Mixed connective tissue disease
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
Mouth ulcers
  • 21.93% for females aged 50 (±5) who take Calcitonin-salmon
Musculoskeletal discomfort
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Musculoskeletal pain
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
Nasal congestion
  • 15.79% for females aged 50 (±5) who take Calcitonin-salmon
Nausea
  • 19.3% for females aged 50 (±5) who take Calcitonin-salmon
  • 10.93% for females aged 50 (±5) who take Zantac
Nausea and vomiting
  • 6.31% for females aged 50 (±5) who take Zantac
Neutrophil count increased
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Numbness and tingling
  • 8.77% for females aged 50 (±5) who take Calcitonin-salmon
Oedema peripheral
  • 24.56% for females aged 50 (±5) who take Calcitonin-salmon
Oral candidiasis
  • 10.53% for females aged 50 (±5) who take Calcitonin-salmon
Osteitis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Osteoarthritis
  • 28.95% for females aged 50 (±5) who take Calcitonin-salmon
Osteolysis
  • 21.93% for females aged 50 (±5) who take Calcitonin-salmon
Osteomyelitis
  • 26.32% for females aged 50 (±5) who take Calcitonin-salmon
Osteonecrosis of jaw
  • 24.56% for females aged 50 (±5) who take Calcitonin-salmon
Osteopenia
  • 23.68% for females aged 50 (±5) who take Calcitonin-salmon
Osteoporosis
  • 27.19% for females aged 50 (±5) who take Calcitonin-salmon
Osteosclerosis
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
Otitis externa
  • 12.28% for females aged 50 (±5) who take Calcitonin-salmon
Paget's disease
  • 26.32% for females aged 50 (±5) who take Calcitonin-salmon
Pain
  • 30.7% for females aged 50 (±5) who take Calcitonin-salmon
  • 6.36% for females aged 50 (±5) who take Zantac
Pain in extremity
  • 7.89% for females aged 50 (±5) who take Calcitonin-salmon
Pain in jaw
  • 28.07% for females aged 50 (±5) who take Calcitonin-salmon
Paraesthesia
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Periodontal disease
  • 21.93% for females aged 50 (±5) who take Calcitonin-salmon
Periodontitis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Platelet count increased
  • 17.54% for females aged 50 (±5) who take Calcitonin-salmon
Pleural effusion
  • 23.68% for females aged 50 (±5) who take Calcitonin-salmon
Pneumonia
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
Polycythemia vera
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
Poor dental condition
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Pulpitis dental
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Rashes
  • 5.56% for females aged 50 (±5) who take Zantac
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Rectal haemorrhage
  • 7.89% for females aged 50 (±5) who take Calcitonin-salmon
Rotator cuff syndrome
  • 25.44% for females aged 50 (±5) who take Calcitonin-salmon
Scab
  • 15.79% for females aged 50 (±5) who take Calcitonin-salmon
Scan bone marrow abnormal
  • 14.04% for females aged 50 (±5) who take Calcitonin-salmon
Sepsis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Sinusitis
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
Sinusitis - chronic
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
Spinal osteoarthritis
  • 28.95% for females aged 50 (±5) who take Calcitonin-salmon
Spondylolisthesis
  • 6.14% for females aged 50 (±5) who take Calcitonin-salmon
Stable angina
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Stomatitis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Stress and anxiety
  • 19.3% for females aged 50 (±5) who take Calcitonin-salmon
Swallowing difficulty
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
Swelling
  • 21.93% for females aged 50 (±5) who take Calcitonin-salmon
Swelling face
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Systemic lupus erythematosus
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Systemic sclerosis (scleroderma)
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Telangiectasia
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Thrombocytosis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Tooth abscess
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Tooth disorder
  • 21.93% for females aged 50 (±5) who take Calcitonin-salmon
Tooth extraction
  • 15.79% for females aged 50 (±5) who take Calcitonin-salmon
Tooth injury
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Transient ischaemic attack
  • 8.77% for females aged 50 (±5) who take Calcitonin-salmon
Traumatic injury of the bladder and urethra
  • 22.81% for females aged 50 (±5) who take Calcitonin-salmon
Traumatic renal injury
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Tricuspid valve incompetence
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Tympanic membrane disorder
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Ulcerative colitis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Urine output - decreased
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Uterine enlargement
  • 10.53% for females aged 50 (±5) who take Calcitonin-salmon
Uterine leiomyoma
  • 25.44% for females aged 50 (±5) who take Calcitonin-salmon
Vasculitis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Vitreous detachment
  • 19.3% for females aged 50 (±5) who take Calcitonin-salmon
Weakness
  • 13.16% for females aged 50 (±5) who take Calcitonin-salmon
  • 6.16% for females aged 50 (±5) who take Zantac
Wegener's granulomatosis
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Weight decreased
  • 19.3% for females aged 50 (±5) who take Calcitonin-salmon
Wound infection staphylococcal
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon

Most common co-existing conditions:

Constipation
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
Depression
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
  • 6.71% for females aged 50 (±5) who take Zantac
High blood cholesterol
  • 6.22% for females aged 50 (±5) who take Zantac
High blood pressure
  • 7.82% for females aged 50 (±5) who take Zantac
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
Hypercalcaemia
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Multiple myeloma
  • 8.77% for females aged 50 (±5) who take Calcitonin-salmon
Multiple sclerosis
  • 7.89% for females aged 50 (±5) who take Calcitonin-salmon
Osteoporosis
  • 44.74% for females aged 50 (±5) who take Calcitonin-salmon
Pain
  • 7.44% for females aged 50 (±5) who take Zantac
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Rheumatoid arthritis
  • 10.53% for females aged 50 (±5) who take Calcitonin-salmon
  • 6.78% for females aged 50 (±5) who take Zantac
Supplementation therapy
  • 5.26% for females aged 50 (±5) who take Calcitonin-salmon
Systemic lupus erythematosus
  • 21.05% for females aged 50 (±5) who take Calcitonin-salmon
Thrombocytopenia
  • 7.02% for females aged 50 (±5) who take Calcitonin-salmon
back to top

Males aged 50 to 59 :

3,509 related reports were analyzed:

Most common symptoms:

Anhedonia
  • 10.0% for males aged 50 (±5) who take Calcitonin-salmon
Aortic arteriosclerosis
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Aortic dilatation
  • 22.0% for males aged 50 (±5) who take Calcitonin-salmon
Back disorder
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Back pain
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Bone density decreased
  • 22.0% for males aged 50 (±5) who take Calcitonin-salmon
Bone disorder
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Cervicobrachial syndrome
  • 20.0% for males aged 50 (±5) who take Calcitonin-salmon
Chest pain
  • 5.58% for males aged 50 (±5) who take Zantac
Chronic obstructive pulmonary disease
  • 28.0% for males aged 50 (±5) who take Calcitonin-salmon
Deformity
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Dyspnea
  • 14.0% for males aged 50 (±5) who take Calcitonin-salmon
Ear pain
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Emphysema
  • 22.0% for males aged 50 (±5) who take Calcitonin-salmon
Enlarged heart
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Erection problems
  • 26.0% for males aged 50 (±5) who take Calcitonin-salmon
Fall
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Fatigue
  • 22.0% for males aged 50 (±5) who take Calcitonin-salmon
  • 6.5% for males aged 50 (±5) who take Zantac
Femur fracture
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Fever
  • 6.62% for males aged 50 (±5) who take Zantac
Foot fracture
  • 20.0% for males aged 50 (±5) who take Calcitonin-salmon
Gait disturbance
  • 18.0% for males aged 50 (±5) who take Calcitonin-salmon
Gingival disorder
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Headache
  • 26.0% for males aged 50 (±5) who take Calcitonin-salmon
Hearing loss
  • 10.0% for males aged 50 (±5) who take Calcitonin-salmon
Heart attack
  • 5.0% for males aged 50 (±5) who take Zantac
Hypercalcaemia
  • 10.0% for males aged 50 (±5) who take Calcitonin-salmon
Hypoaesthesia
  • 16.0% for males aged 50 (±5) who take Calcitonin-salmon
Infection
  • 26.0% for males aged 50 (±5) who take Calcitonin-salmon
Influenza like illness
  • 14.0% for males aged 50 (±5) who take Calcitonin-salmon
Injury
  • 12.0% for males aged 50 (±5) who take Calcitonin-salmon
Insomnia
  • 26.0% for males aged 50 (±5) who take Calcitonin-salmon
Internal fixation of fracture
  • 12.0% for males aged 50 (±5) who take Calcitonin-salmon
Intervertebral disc degeneration
  • 22.0% for males aged 50 (±5) who take Calcitonin-salmon
Itching
  • 12.0% for males aged 50 (±5) who take Calcitonin-salmon
Jaw fracture
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Joint pain
  • 36.0% for males aged 50 (±5) who take Calcitonin-salmon
Kyphosis
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Laryngeal nerve damage
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Lung hyperinflation
  • 22.0% for males aged 50 (±5) who take Calcitonin-salmon
Muscle spasms
  • 10.0% for males aged 50 (±5) who take Calcitonin-salmon
Nausea
  • 26.0% for males aged 50 (±5) who take Calcitonin-salmon
  • 6.71% for males aged 50 (±5) who take Zantac
Nausea and vomiting
  • 20.0% for males aged 50 (±5) who take Calcitonin-salmon
Neoplasm skin
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Oedema
  • 26.0% for males aged 50 (±5) who take Calcitonin-salmon
Oedema peripheral
  • 30.0% for males aged 50 (±5) who take Calcitonin-salmon
Oral infection
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Oral pain
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Osteoarthritis
  • 26.0% for males aged 50 (±5) who take Calcitonin-salmon
Osteogenesis imperfecta
  • 20.0% for males aged 50 (±5) who take Calcitonin-salmon
Osteomyelitis
  • 22.0% for males aged 50 (±5) who take Calcitonin-salmon
Osteonecrosis of jaw
  • 20.0% for males aged 50 (±5) who take Calcitonin-salmon
Osteopenia
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Osteoporosis
  • 28.0% for males aged 50 (±5) who take Calcitonin-salmon
Pain
  • 40.0% for males aged 50 (±5) who take Calcitonin-salmon
  • 5.93% for males aged 50 (±5) who take Zantac
Pain in extremity
  • 32.0% for males aged 50 (±5) who take Calcitonin-salmon
Pain in jaw
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Pathological fracture
  • 20.0% for males aged 50 (±5) who take Calcitonin-salmon
Rashes
  • 10.0% for males aged 50 (±5) who take Calcitonin-salmon
Rib fracture
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Sinus headache
  • 20.0% for males aged 50 (±5) who take Calcitonin-salmon
Sinusitis
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Sinusitis - chronic
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Spinal compression fracture
  • 20.0% for males aged 50 (±5) who take Calcitonin-salmon
Spinal cord compression
  • 22.0% for males aged 50 (±5) who take Calcitonin-salmon
Spinal fracture
  • 26.0% for males aged 50 (±5) who take Calcitonin-salmon
Stress and anxiety
  • 14.0% for males aged 50 (±5) who take Calcitonin-salmon
Surgery
  • 14.0% for males aged 50 (±5) who take Calcitonin-salmon
Swelling
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Swelling face
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Tooth extraction
  • 14.0% for males aged 50 (±5) who take Calcitonin-salmon
Tumor
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Ulna fracture
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon
Upper airway obstruction
  • 16.0% for males aged 50 (±5) who take Calcitonin-salmon
Weakness
  • 18.0% for males aged 50 (±5) who take Calcitonin-salmon
  • 5.2% for males aged 50 (±5) who take Zantac
Weight increased
  • 24.0% for males aged 50 (±5) who take Calcitonin-salmon

Most common co-existing conditions:

High blood pressure
  • 6.13% for males aged 50 (±5) who take Zantac
Osteoporosis
  • 12.0% for males aged 50 (±5) who take Calcitonin-salmon
Pain
  • 6.36% for males aged 50 (±5) who take Zantac
back to top

Do you take Calcitonin-salmon and Zantac:

  • To personalize this prediction to you, including to your gender, age, personal and family history, and more: Click here

Related studies

Calcitonin-salmon

Calcitonin-salmon has active ingredients of calcitonin, salmon. (latest outcomes from Calcitonin-salmon 1,149 users)

Zantac

Zantac has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. (latest outcomes from Zantac 58,762 users)

General study

Recent updates

Recent general studies
Recent personal studies

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on ePatient.care is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the ePatient.care site and its content is at your own risk.

Submit your testimonial

  • Please fill in your Testimonial.
  • Please enter a minimum of 10 characters for your Testimonial.
  • Please fill in your Name.

Please wait...

{progressItem}

Thank you!